<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="4.3.2">Jekyll</generator><link href="/marralab/preview/pr-36/feed.xml" rel="self" type="application/atom+xml" /><link href="/marralab/preview/pr-36/" rel="alternate" type="text/html" /><updated>2024-11-15T00:57:56+00:00</updated><id>/marralab/preview/pr-36/feed.xml</id><title type="html">MATCH Lab</title><subtitle>Multiomic Analysis of Treatment Resistance and Cancer Heterogeneity</subtitle><entry><title type="html">Journal Club 2</title><link href="/marralab/preview/pr-36/2024/09/04/journal-club-2.html" rel="alternate" type="text/html" title="Journal Club 2" /><published>2024-09-04T00:00:00+00:00</published><updated>2024-11-15T00:56:38+00:00</updated><id>/marralab/preview/pr-36/2024/09/04/journal-club-2</id><content type="html" xml:base="/marralab/preview/pr-36/2024/09/04/journal-club-2.html"><![CDATA[<h2 id="presented-by-signe">Presented by Signe</h2>
<p><strong>Title:</strong> <a href="https://doi.org/10.1038/s41588-024-01851-2">The correlation between CpG methylation and gene expression is driven by sequence variants</a></p>

<p><strong>Authors:</strong> Olafur Andri Stefansson, et al.</p>

<p><strong>Journal:</strong> Nature Genetics</p>

<p><strong>Year:</strong> August 2024</p>

<p><strong>Abstract:</strong></p>

<p>Gene promoter and enhancer sequences are bound by transcription factors and are depleted of methylated CpG sites (cytosines preceding guanines in DNA). The absence of methylated CpGs in these sequences typically correlates with increased gene expression, indicating a regulatory role for methylation. We used nanopore sequencing to determine haplotype-specific methylation rates of 15.3 million CpG units in 7,179 whole-blood genomes. We identified 189,178 methylation depleted sequences where three or more proximal CpGs were unmethylated on at least one haplotype. A total of 77,789 methylation depleted sequences (~41%) associated with 80,503 cis-acting sequence variants, which we termed allele-specific methylation quantitative trait loci (ASM-QTLs). RNA sequencing of 896 samples from the same blood draws used to perform nanopore sequencing showed that the ASM-QTL, that is, DNA sequence variability, drives most of the correlation found between gene expression and CpG methylation. ASM-QTLs were enriched 40.2-fold (95% confidence interval 32.2, 49.9) among sequence variants associating with hematological traits, demonstrating that ASM-QTLs are important functional units in the noncoding genome.</p>]]></content><author><name>signe-maclennan</name></author><category term="DNA sequencing" /><category term="Epigenetics" /><category term="Gene expression" /><category term="Genome-wide association studies" /><category term="Genomics" /><summary type="html"><![CDATA[Presented by Signe Title: The correlation between CpG methylation and gene expression is driven by sequence variants]]></summary></entry><entry><title type="html">Journal Club 1</title><link href="/marralab/preview/pr-36/2024/05/29/journal-club-1.html" rel="alternate" type="text/html" title="Journal Club 1" /><published>2024-05-29T00:00:00+00:00</published><updated>2024-11-15T00:56:38+00:00</updated><id>/marralab/preview/pr-36/2024/05/29/journal-club-1</id><content type="html" xml:base="/marralab/preview/pr-36/2024/05/29/journal-club-1.html"><![CDATA[<h2 id="presented-by-hayley-steif-lab">Presented by Hayley (Steif Lab)</h2>
<p><strong>Title:</strong> <a href="https://doi.org/10.1016/j.cell.2022.03.033">Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche</a></p>

<p><strong>Authors:</strong> Pilar Baldominos, et al.</p>

<p><strong>Journal:</strong> Cell</p>

<p><strong>Year:</strong> 2022</p>

<p><strong>Highlights:</strong></p>

<ul>
  <li>Antigen-expressing tumor cells that escape from T cell attack are quiescent.</li>
  <li>Quiescent cancer cells (QCCs) form clusters that exclude immune infiltrates.</li>
  <li>PADME-seq reveals an increase in terminally exhausted T cells in the QCC niche.</li>
  <li>HIF1a activation in cancer cells augments T cell exhaustion and reduces T cell killing.</li>
</ul>]]></content><author><name>Guest</name></author><category term="Cell cycle" /><category term="TNBC" /><category term="Immunotherapy" /><category term="Drug resistance" /><summary type="html"><![CDATA[Presented by Hayley (Steif Lab) Title: Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche]]></summary></entry></feed>